500 related articles for article (PubMed ID: 37476590)
21. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
[TBL] [Abstract][Full Text] [Related]
22. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
23. Potential Roles of the Gut Microbiota in Pancreatic Carcinogenesis and Therapeutics.
Yang Q; Zhang J; Zhu Y
Front Cell Infect Microbiol; 2022; 12():872019. PubMed ID: 35463649
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiome in cancer immunotherapy: Current trends, translational challenges and future possibilities.
Pandey P; Khan F
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130401. PubMed ID: 37307905
[TBL] [Abstract][Full Text] [Related]
25. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
26. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
[TBL] [Abstract][Full Text] [Related]
27. Microbiota: A key factor affecting and regulating the efficacy of immunotherapy.
Jiang Y; Jia D; Sun Y; Ding N; Wang L
Clin Transl Med; 2023 Dec; 13(12):e1508. PubMed ID: 38082435
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral microbiota: implications for cancer onset, progression, and therapy.
Wu J; Zhang P; Mei W; Zeng C
Front Immunol; 2023; 14():1301506. PubMed ID: 38292482
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiome and cancer immunotherapy.
Li W; Deng Y; Chu Q; Zhang P
Cancer Lett; 2019 Apr; 447():41-47. PubMed ID: 30684593
[TBL] [Abstract][Full Text] [Related]
30. The impact of modulating the gastrointestinal microbiota in cancer patients.
Morkūnas E; Skiecevičienė J; Kupčinskas J
Best Pract Res Clin Gastroenterol; 2020; 48-49():101700. PubMed ID: 33317795
[TBL] [Abstract][Full Text] [Related]
31. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients.
Sammallahti H; Kokkola A; Rezasoltani S; Ghanbari R; Asadzadeh Aghdaei H; Knuutila S; Puolakkainen P; Sarhadi VK
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884776
[TBL] [Abstract][Full Text] [Related]
32. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy.
Sevcikova A; Izoldova N; Stevurkova V; Kasperova B; Chovanec M; Ciernikova S; Mego M
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008915
[TBL] [Abstract][Full Text] [Related]
33. An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome.
Jiang S; Ma W; Ma C; Zhang Z; Zhang W; Zhang J
Gut Microbes; 2024; 16(1):2341717. PubMed ID: 38717360
[TBL] [Abstract][Full Text] [Related]
34. The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma.
Kaźmierczak-Siedlecka K; Stachowska E; Folwarski M; Przewłócka K; Makarewicz W; Bryl E
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7275-7284. PubMed ID: 34919227
[TBL] [Abstract][Full Text] [Related]
35. The role of the gut microbiome in gastrointestinal cancers.
Mishra Y; Ranjan A; Mishra V; Chattaraj A; Aljabali AAA; El-Tanani M; Hromić-Jahjefendić A; Uversky VN; Tambuwala MM
Cell Signal; 2024 Mar; 115():111013. PubMed ID: 38113978
[TBL] [Abstract][Full Text] [Related]
36. Critical role of the gut microbiota in immune responses and cancer immunotherapy.
Li Z; Xiong W; Liang Z; Wang J; Zeng Z; Kołat D; Li X; Zhou D; Xu X; Zhao L
J Hematol Oncol; 2024 May; 17(1):33. PubMed ID: 38745196
[TBL] [Abstract][Full Text] [Related]
37. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
38. Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies.
Chen Y; Wang X; Ye Y; Ren Q
Med Oncol; 2023 Dec; 41(1):25. PubMed ID: 38129370
[TBL] [Abstract][Full Text] [Related]
39. Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer.
Hou X; Zheng Z; Wei J; Zhao L
Front Immunol; 2022; 13():1030745. PubMed ID: 36426359
[TBL] [Abstract][Full Text] [Related]
40. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
